DNA methylation analysis within the IL2RA gene promoter in youth with autoimmune thyroid disease.
DNA methylation
Graves' disease
Hashimoto thyroiditis
autoimmune thyroid disease
children and adolescents
interleukin 2 receptor alpha-subunit
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
29
09
2019
revised:
17
12
2019
accepted:
08
01
2020
pubmed:
17
1
2020
medline:
17
3
2020
entrez:
17
1
2020
Statut:
ppublish
Résumé
Alpha-subunit of the interleukin-2 receptor (IL2RA) is involved in the regulation of T-cell function and has been related to autoimmune thyroid disease (AITD). Although the exact mechanisms are not fully understood, promoter methylation might account for differences in gene expression. The aim of this study was to investigate whether there are differences in the percentage of DNA methylation within the IL2RA gene promoter in young patients with AITD. In a cross-sectional design, the presence of DNA methylation in the IL2RA gene promoter was quantified, by real-time PCR and melting curve analysis, in modified genomic DNA isolated from blood samples of a total of 149 children and adolescents with AITD, including patients with Hashimoto thyroiditis (ΗΤ) (n = 60), Graves' disease (GD) (n = 9), concurrent diagnosis of HT and type 1 diabetes (T1DM + HT) (n = 25), and healthy controls (n = 55). The percentage of DNA methylation in the IL2RA gene promoter was significantly decreased in patients with GD (26.0 ± 4.2%) but not in those with HT (36.3 ± 1.4%) in comparison with controls (41.3 ± 1.5%). The observed DNA hypomethylation in the IL2RA gene promoter in patients with GD might be related to its increased expression, thus contributing to the etiopathogenesis of GD in childhood and adolescence.
Sections du résumé
BACKGROUND
BACKGROUND
Alpha-subunit of the interleukin-2 receptor (IL2RA) is involved in the regulation of T-cell function and has been related to autoimmune thyroid disease (AITD). Although the exact mechanisms are not fully understood, promoter methylation might account for differences in gene expression. The aim of this study was to investigate whether there are differences in the percentage of DNA methylation within the IL2RA gene promoter in young patients with AITD.
MATERIALS AND METHODS
METHODS
In a cross-sectional design, the presence of DNA methylation in the IL2RA gene promoter was quantified, by real-time PCR and melting curve analysis, in modified genomic DNA isolated from blood samples of a total of 149 children and adolescents with AITD, including patients with Hashimoto thyroiditis (ΗΤ) (n = 60), Graves' disease (GD) (n = 9), concurrent diagnosis of HT and type 1 diabetes (T1DM + HT) (n = 25), and healthy controls (n = 55).
RESULTS
RESULTS
The percentage of DNA methylation in the IL2RA gene promoter was significantly decreased in patients with GD (26.0 ± 4.2%) but not in those with HT (36.3 ± 1.4%) in comparison with controls (41.3 ± 1.5%).
CONCLUSIONS
CONCLUSIONS
The observed DNA hypomethylation in the IL2RA gene promoter in patients with GD might be related to its increased expression, thus contributing to the etiopathogenesis of GD in childhood and adolescence.
Substances chimiques
IL2RA protein, human
0
Interleukin-2 Receptor alpha Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13199Subventions
Organisme : Research Committee of the Aristotle University of Thessaloniki
ID : 89650
Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation.
Références
Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174-180.
Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014;170:R241-R252.
Davies TF, Latif R, Yin X. New genetic insights from autoimmune thyroid disease. J Thyroid Res. 2012;2012:623852.
Cooper JD, Simmonds MJ, Walker NM, et al. Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet. 2012;21:5202-5208.
McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252-265.
Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev. 2013;29:8-18.
Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol. 2014;9:147-156.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(S3):245-254.
Ajjan RA, Weetman AP. Cytokines in thyroid autoimmunity. Autoimmunity. 2003;36:351-359.
Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65:150-155.
van der Heul-Nieuwenhuijsen L, Padmos RC, Drexhage RC, de Wit H, Berghout A, Drexhage HA. An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients. J Clin Endocrinol Metab. 2010;95:1962-1971.
Wang J, Wicker LS, Santamaria P. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin Immunol. 2009;21:363-371.
Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet. 2005;76:773-779.
Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007;39:1074-1082.
Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves’ disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf). 2007;66:508-512.
International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851-862.
Barton A, Thomson W, Ke X, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet. 2008;40:1156-1159.
Smith KA. The quantal theory of how the immune system discriminates between "self and non-self". Med Immunol. 2004;3:3.
Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol. 2003;109:37-45.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35-53.
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391-397.
Alisch RS, Barwick BG, Chopra P, et al. Age-associated DNA methylation in pediatric populations. Genome Res. 2012;22:623-632.
Wettinger SB, Doggen CJ, Spek CA, Rosendaal FR, Reitsma PH. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood. 2005;105:2000-2006.
Smith E, Jones ME, Drew PA. Quantitation of DNA methylation by melt curve analysis. BMC Cancer. 2009;9:123.
Kurdyukov S, Bullock MDNA. Methylation analysis: choosing the right method. Biology (Basel). 2016;5:pii:E3.
Lorente A, Mueller W, Urdangarín E, Lázcoz P, von Deimling A, Castresana JS. Detection of methylation in promoter sequences by melting curve analysis-based semi-quantitative real time PCR. BMC Cancer. 2008;8:61.
Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35:e41.
Amornpisutt R, Sriraksa R, Limpaiboon T. Validation of methylation-sensitive high resolution melting for the detection of DNA methylation in cholangiocarcinoma. Clin Biochem. 2012;45:1092-1094.
Arroyo-Jousse V, Garcia-Diaz DF, Codner E, Pérez-Bravo F. Epigenetics in type 1 diabetes: TNFa gene promoter methylation status in Chilean patients with type 1 diabetes mellitus. Br J Nutr. 2016;116:1861-1868.
Shalaby SM, Mackawy AMH, Atef DM, Atef RM, Saeed J. Promoter methylation and expression of intercellular adhesion molecule 1 gene in blood of autoimmune thyroiditis patients. Mol Biol Rep. 2019;46:5345-5353.
Morita E, Watanabe M, Inoue N, et al. Methylation levels of the TNFA gene are different between Graves' and Hashimoto's diseases and influenced by the TNFA polymorphism. Autoimmunity. 2018;51:118-125.
Shu Y, Hu Q, Long H, Chang C, Lu Q, Xiao R. Epigenetic variability of CD4+CD25+ Tregs contributes to the pathogenesis of autoimmune diseases. Clin Rev Allergy Immunol. 2017;52:260-272.
Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482-487.
Sempere-Ortells JM, Pérez-García V, Marín-Alberca G, et al. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity. 2009;42:636-645.
Fransson M, Burman J, Lindqvist C, Atterby C, Fagius J, Loskog A. T regulatory cells lacking CD25 are increased in MS during relapse. Autoimmunity. 2010;43:590-597.
Aoki CA, Roifman CM, Lian ZX, et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun. 2006;27:50-53.
Cerosaletti K, Schneider A, Schwedhelm K, et al. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS ONE. 2013;8:e83811.
Garg G, Tyler JR, Yang JH, et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol. 2012;188:4644-4653.
Belot MP, Fradin D, Mai N, et al. CpG methylation changes within the IL2RA promoter in Type 1 diabetes of childhood onset. PLoS ONE. 2013;8:e68093.
Field J, Fox A, Jordan MA, et al. Interleukin-2 receptor-α proximal promoter hypomethylation is associated with multiple sclerosis. Genes Immun. 2017;18:59-66.
Wang B, Shao X, Song R, Xu D, Zhang JA. The emerging role of epigenetics in autoimmune thyroid diseases. Front Immunol. 2017;8:396.
Coppedè F. Epigenetics and autoimmune thyroid diseases. Front Endocrinol (Lausanne). 2017;8:149.
Cai TT, Muhali FS, Song RH, et al. Genome-wide DNA methylation analysis in Graves’ disease. Genomics. 2015;105:204-210.
Limbach M, Saare M, Tserel L, et al. Epigenetic profiling in CD4+ and CD8+ T cells from Graves’ disease patients reveals changes in genes associated with T cell receptor signaling. J Autoimmun. 2016;67:46-56.
Hashimoto H, Watanabe M, Inoue N, et al. Association of IFNG gene methylation in peripheral blood cells with the development and prognosis of autoimmune thyroid diseases. Cytokine. 2019;123:154770.
Xin Z, Hua L, Shi TT, et al. A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves' orbitopathy. J Endocrinol Invest. 2018;41:719-727.
Arakawa Y, Watanabe M, Inoue N, Sarumaru M, Hidaka Y, Iwatani Y. Association of polymorphisms in DNMT1, DNMT3A, DNMT3B, MTHFR and MTRR genes with global DNA methylation levels and prognosis of autoimmune thyroid disease. Clin Exp Immunol. 2012;170:194-201.
Cai TT, Zhang J, Wang X, et al. Gene-gene and gene-sex epistatic interactions of DNMT1, DNMT3A and DNMT3B in autoimmune thyroid disease. Endocr J. 2016;63:643-653.
Mao R, Fan Y, Zuo L, et al. Association study between methylenetetrahydrofolate reductase gene polymorphisms and Graves’ disease. Cell Biochem Funct. 2010;28:585-590.
Lee JY, Kim NK, Cho YW, Lew H. Association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and susceptibility to Graves’ ophthalmopathy. Mol Med Rep. 2016;14:2276-2282.
Guo Q, Wu D, Yu H, et al. Alterations of global DNA methylation and DNA methyltransferase expression in T and B lymphocytes from patients with newly diagnosed autoimmune thyroid diseases after treatment: a follow-up study. Thyroid. 2018;28:377-385.
Liu T, Sun J, Wang Z, et al. Changes in the DNA methylation and hydroxymethylation status of the intercellular adhesion molecule 1 gene promoter in thyrocytes from autoimmune thyroiditis patients. Thyroid. 2017;27:838-845.
Regulatory KB. B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Dan Med J. 2016;63:pii:B5177.
Ramos-Leví AM, Marazuela M. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr. 2016;63:421-429.
Heuer M, Aust G, Ode-Hakim S, Scherbaum WA. Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid. 1996;6:97-106.
Rostamzadeh D, Dabbaghmanesh MH, Shabani M, Hosseini A, Amirghofran Z. Expression profile of human Fc receptor-like 1, 2, and 4 molecules in peripheral blood mononuclear cells of patients with Hashimoto's thyroiditis and Graves' disease. Horm Metab Res. 2015;47:693-698.
Mingari MC, Gerosa F, Carra G, et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature. 1984;312:641-643.
Kristensen B, Hegedüs L, Lundy SK, Brimnes MK, Smith TJ, Nielsen CH. Characterization of regulatory B cells in Graves' disease and Hashimoto's thyroiditis. PLoS ONE. 2015;10:e0127949.